Sociedad Americana de Hirudoterapia

Hirudins and fenestrins of the African medicinal leech Asiaticobdella fenestrata

Basic science / preclinical published in Parasitol Res (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genómica y proteómicaFarmacología salivalSchulz L et al. · Parasitology research, 2025

Abstract

African hematophagous leeches are largely underinvestigated both in terms of their biodiversity and the characterization of the repertoire of bioactive components of their salivary gland secretions. Asiaticobdella (formerly Aliolimnatis) fenestrata Moore, 1939, also referred to as the African medicinal leech, is hence a promising candidate for the identification and functional characterization of putative anticoagulants that may serve as inspirations for the development of new or the enhancement of existing drugs for medical purposes. A. fenestrata inhabits flooded plains of southern African regions and mainly feeds on mammals like black lechwe (Kobus leche Gray, 1850). Whereas several anticoagulants, including two putative hirudins of A. fenestrata, have already been identified in previous investigations, functional characterizations of these components are yet missing. We conducted an in-depth re-analysis of the salivary gland transcriptomic data set of A. fenestrata and identified two additional hirudin-like factors that exhibit a remarkable structural feature-the presence of an RGD motif at or near the N-terminal end of the molecules. The presence of such an RGD motif is a key feature of leech-derived platelet aggregation inhibitors such as ornatins and decorsins. However, both in ornatins and in decorsins, the respective RGD motif is located within the molecule between the 5th and the 6th cysteine residues, but not at or near the N-terminus. We named the two putative platelet aggregation inhibitors "fenestrins." Both the two putative hirudins and the two fenestrins of A. fenestrata were expressed as recombinant proteins, purified, and functionally characterized in either coagulation or platelet aggregation assays.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsLeechesSalivary GlandsHirudinsAnticoagulantsAmino Acid SequenceGene Expression Profiling

Resumen

Identification of two additional hirudin-like factors with N-terminal RGD motifs in the African leech Asiaticobdella fenestrata, named 'fenestrins'. Recombinant expression and functional characterization in coagulation and platelet-aggregation assays.

Por qué esto importa para la hirudoterapia

This study conducted an in-depth re-analysis of salivary gland transcriptomic data from Asiaticobdella fenestrata (African medicinal leech), identifying two additional hirudin-like factors and two novel putative platelet aggregation inhibitors named 'fenestrins,' which uniquely carry an RGD motif at or near the N-terminus — distinct from the internal RGD position found in decorsins and ornatins. All four factors were expressed as recombinant proteins and functionally characterized in coagulation or platelet aggregation assays. This work expands the known antithrombotic repertoire of leech salivary secretions and identifies a structurally novel class of leech-derived platelet inhibitors, directly relevant to ASH's domain. Caveat: Findings are preclinical, based on recombinant characterization; no clinical or in-vivo data are presented.

Citación

Hirudins and fenestrins of the African medicinal leech Asiaticobdella fenestrata.

Schulz L et al. · Parasitology research, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.